Evidence map›Paper›PMID 37676605›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Applications of Big Data and AI-Driven Technologies in CADD (Computer-Aided Drug Design).

Seongmin Seo, Jai Woo Lee

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Seongmin SeoDepartment of Mechanical Engineering, Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea.
Jai Woo LeeDepartment of Big Data Science, College of Public Policy, Korea University, Sejong, Republic of Korea. jaiwoolee@korea.ac.kr.ORCID 0000-0002-4385-2831

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the field of computer-aided drug design (CADD), there has been dramatic progress in the development of big data and AI-driven methodologies. The expensive and time-consuming process of drug design is related to biomedical complexity. CADD can be used to apply effective and efficient strategies to overcome obstacles in the field of drug design in order to properly design and develop a new medicine. To prepare the raw data for consistent and repeatable applications of big data and AI methodologies, data pre-processing methods are introduced. Big data and AI technologies can be used to develop drugs in areas including predicting absorption, distribution, metabolism, excretion, and toxicity properties as well as finding binding sites in target proteins and conducting structure-based virtual screenings. The accurate and thorough analysis of large amounts of biomedical data as well as the design of prediction models in the area of drug design is made possible by data pre-processing and applications of big data and AI skills. In the biomedical big data era, knowledge on the biological, chemical, or pharmacological structures of biomedical entities relevant to drug design should be analyzed with significant big data and AI approaches.

Indexed as

Big DataBody FluidsArtificial IntelligenceBinding SitesDrug DesignArtificial intelligenceBig DataComputer-aided drug designMathematical modelingStatistics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.